David Tsao Sells 10,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 10,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $92.86, for a total value of $928,600.00. Following the completion of the transaction, the chief technology officer directly owned 1,000 shares of the company’s stock, valued at approximately $92,860. This trade represents a 90.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $102.27, for a total transaction of $2,045,400.00.

Billiontoone Trading Down 3.5%

Shares of BLLN stock opened at $94.04 on Friday. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $150.44. The stock has a market cap of $4.32 billion and a price-to-earnings ratio of 134.34. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69. The firm has a fifty day moving average of $116.49 and a 200-day moving average of $94.60.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. The company had revenue of $109.45 million during the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. On average, equities research analysts forecast that Billiontoone, Inc. will post 0.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Guggenheim started coverage on Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective on the stock. JPMorgan Chase & Co. cut their target price on Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research report on Thursday, August 6th. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. BTIG Research lowered their price target on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $126.71.

Institutional Trading of Billiontoone

Large investors have recently added to or reduced their stakes in the company. Wasatch Advisors LP boosted its holdings in shares of Billiontoone by 40.2% in the 2nd quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after acquiring an additional 148,446 shares in the last quarter. Thrive Wealth Management LLC acquired a new stake in Billiontoone during the 2nd quarter valued at $240,000. Perceptive Advisors LLC raised its position in Billiontoone by 26.1% in the 1st quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock valued at $7,248,000 after purchasing an additional 19,000 shares during the last quarter. Bank of America Corp DE boosted its stake in Billiontoone by 8,603.4% in the first quarter. Bank of America Corp DE now owns 12,707 shares of the company’s stock worth $1,003,000 after purchasing an additional 12,561 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Billiontoone by 151.8% in the first quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company’s stock worth $2,408,000 after purchasing an additional 18,389 shares in the last quarter.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.